European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who...

Related Keywords

Japan ,Leuven ,Region Flamande ,Belgium ,Japanese ,Gastroenterol Hepatol ,Exchange Commission ,Abbvie Ltd ,University Hospital Leuven ,Crohn Colitis Foundation ,Allergan ,Abbvie News Center ,Adapted Mayo Score ,Mucosal Healing ,Lancetin May ,Important Safety Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Accessed April ,Long Term Safety ,Ulcerative Colitis ,Published November ,Global Burden ,Disease Study ,Movie News ,Published February ,Published March ,Published June ,Published December ,Severely Active Ulcerative ,Maintenance Therapy ,Severely Active Ulcerative Colitis ,Takayasu Arteritis ,Evaluate Efficacy ,Adult Participants ,Giant Cell ,Long Term Extension Study ,Disease Who Completed ,Adapted Mayo ,Abbvie ,